What is MS Phase 2 Study Nerispirdine (HP184)?

Category: Others

false

See also: Clinical Trial

NCT00772525 is a double-blind, placebo-controlled, randomized crossover, activity study of single oral doses of 50 mg and 400 mg nerispirdine (HP184) on visual function in patients with multiple sclerosis. Other study name is ACT10573. This is a completed study.

No patients have reported taking MS Phase 2 Study Nerispirdine (HP184).
Last updated:
There are no evaluations for MS Phase 2 Study Nerispirdine (HP184).